SOLICITATION NOTICE
A -- Technetium for Pharmaceuticals
- Notice Date
- 2/20/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Energy, Pacific Northwest National Laboratory - Battelle (DOE Contractor), PNNL Licensing, PO Box 999, MSIN K9-89, Richland, WA, 99352
- ZIP Code
- 99352
- Solicitation Number
- Reference-Number-11936-E
- Response Due
- 4/1/2002
- Archive Date
- 4/16/2002
- Point of Contact
- Connie Mitzel-Faulk, Licensing Staff, Phone (509) 375-6401, Fax (509) 375-6731,
- E-Mail Address
-
technology@pnl.gov
- Description
- Pacific Northwest National Laboratory (PNNL), operated by Battelle Memorial Institute under contract to the U.S. Department of Energy, solicits interest from companies interested in obtaining license rights to commercialize, manufacture and market the following technology. License rights may be issued on an exclusive or nonexclusive basis and may include specific fields of use. PNNL may also be available to licensee(s) to assist in further research and development of the technology under a sponsored research agreement or CRADA program. The Technology: Greater than 85% of routine human nuclear diagnostic procedures rely upon technetium because of its excellent radiation characteristics. The reduction of pertechnetate becomes a critical step in exploitation of the full value of this element for diagnosis. Presently, the inorganic compound tin chloride hydrate is the chemical reducing agent used commercially. However, the complex chemistry of tin produces a number of byproducts which may be undesirable, limiting the development and application of test kits with reduced technetium compounds targeted for specific human organs. The new technology presented here is a method, readily adaptable to an end user kit for the microbial reduction of technetium. This microbial direct enzymatic reduction can form a range of products with potential value in targeting different tissues and organs. Importantly, the method produces technetium for pharmaceutical purposes without the byproducts of the existing methodology. Any company interested in licensing this technology must respond with a letter of interest (may be submitted by e-mail) no later than 30 days from the publication date of this Notice summarizing the company?s business and technical expertise and motivation for pursuing this opportunity. Companies deemed appropriate will be provided with further information on the technology. Such information may require an executed Nondisclosure Agreement. Respondents wishing to enter into negotiations for a commercial license will be required to submit a business plan for the commercialization of the technology prior to licensee(s) selection and negotiations. Please send letters of interest to the attention of the POC identified within this Notice.
- Record
- SN00028339-W 20020222/020220213108 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |